

**21 November 2025**

**Provexis plc**  
**('Provexis' or the 'Company')**

**Result of AGM**

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed. The proxy votes received from shareholders on each resolution are set out below.

<b>Resolutions</b>	<b>Votes for</b> *	<b>%</b>	<b>Votes against</b>	<b>%</b>	<b>Votes total</b> **	<b>Votes withheld</b> ***
Resolution 1	427,923,799	99.95%	205,138	0.05%	428,128,937	71,195
Resolution 2	427,268,369	99.95%	233,145	0.05%	427,501,514	698,618
Resolution 3	425,154,416	99.92%	351,892	0.08%	425,506,308	2,693,824
Resolution 4	424,646,783	99.68%	1,376,909	0.32%	426,023,692	2,176,440
Resolution 5	424,720,543	99.84%	683,027	0.16%	425,403,570	2,796,562
Resolution 6	425,120,537	99.94%	252,638	0.06%	425,373,175	2,826,957
Resolution 7	423,692,950	99.48%	2,218,239	0.52%	425,911,189	2,288,943

\* Includes discretionary votes

\*\* Total votes cast do not include withheld votes

\*\*\* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against' any of the resolutions

For further information please contact:

Provexis plc  
Dawson Buck, Chairman  
Ian Ford, CEO

Tel: 07490 391888

[enquiries@provexis.com](mailto:enquiries@provexis.com)

Allenby Capital Limited  
Nick Naylor / Ashur Joseph

Tel: 020 3328 5656

**Notes for editors**

**About Provexis plc**

AIM quoted Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

Fruitflow is a natural, breakthrough ingredient that helps with platelet aggregation. This helps promote normal blood flow and circulation, which in turn benefits cardiovascular health. Fruitflow helps the platelets to circulate freely and smoothly throughout your blood, without sticking to one another or to the blood vessels themselves. Freely flowing blood helps reduce stress on your cardiovascular system.

Fruitflow is a highly concentrated form of bioactives which is lycopene-free and contains over 30 known anti-platelet compounds. Published clinical studies have shown that Fruitflow works to maintain healthy blood flow in a similar way to 75mg aspirin but with a milder and reversible action; Fruitflow has a similar antiplatelet effect to a single dose of aspirin - but when taken daily, it has none of aspirin's side effects.

The science behind Fruitflow has been validated by leading peer review publications and regulatory authorities. Fruitflow is the only natural antiplatelet to have a health claim approved by the European Food Safety Authority, stating that 150mg of Fruitflow 'helps maintain normal platelet aggregation, which contributes to healthy blood flow'.

Fruitflow has a number of specific health benefits which have been reflected in separate patent filings for the use of

Fruitflow in:

- mitigating exercise-induced inflammation;
- managing blood pressure;
- protecting against the adverse effects of air pollution on the body's cardiovascular system. Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third; and
- conferring health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO, following the completion of a successful human study which is further detailed here [www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html](https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html).

Provexis sells a high quality dietary supplement product containing Fruitflow and Omega-3 from its website [www.fruitflowplus.com](https://www.fruitflowplus.com) on a mail order basis. The product is also available to purchase from Amazon.co.uk.

Provexis has been working with BYHEALTH, a circa £2bn listed Chinese dietary supplement business, for more than eight years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in China are typically required to obtain the necessary regulatory clearances in China, and a significant investment in eight separate Fruitflow studies has been undertaken at BYHEALTH's expense. Completed studies have shown excellent results in use for Fruitflow, and they provide strong evidence for the efficacy of Fruitflow on platelet function.

The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.

In August 2023 the Company was delighted to report that BYHEALTH had submitted: i) the first application for a new permitted health function claim and ii) some related product registration applications.

The significance of these major developments for Fruitflow in China is further outlined here [www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods](https://www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods). BYHEALTH has noted that it has been working on the project since 2015, with 'tens of millions of funds' (RMB) invested by BYHEALTH in the research and development work.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire. Provexis' shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit [www.provexis.com](https://www.provexis.com) and [www.fruitflowplus.com](https://www.fruitflowplus.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](https://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGXFLFLEFLXFBD